Himadri Speciality Chemical Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,691 Cr +57.9% YoYSee revenue, profit and what management said. You are viewing Q3 FY25.
HS

Himadri Speciality Chemical Ltd

Q3 FY25Chemicals & Petrochemicals

Himadri Speciality Chemical Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹1,141Cr
+8.4% YoY
+0.4% QoQ
Net profit
₹141Cr
+29.4% YoY
+3.7% QoQ
Margin
19%
+2 pp YoY
+1 pp QoQ

Based on Himadri Speciality Chemical Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹679
Market cap₹34.1K Cr
P/E42.6

The short version

Q3FY25 Revenue (Standalone): Rs. 1,131.81 Crs, up 7.53% YoY (from Rs. 1,052.51 Crs in Q3FY24) [Page 50]. Q3FY25 EBITDA (Standalone): Rs. 222.34 Crs, up 31.79% YoY (Page 49).

From Himadri Speciality Chemical Ltd's Q3 FY25 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3FY25 Revenue (Standalone): Rs. 1,131.81 Crs, up 7.53% YoY (from Rs. 1,052.51 Crs in Q3FY24) [Page 50]
  • Q3FY25 Revenue (Consolidated): Rs. 1,140.66 Crs, up 8.38% YoY (from Rs. 1,052.51 Crs in Q3FY24) [Page 51]
  • Q3FY25 Sales Volume: 137,447 MT, increased 11% YoY (from 124,024 MT in Q3FY24) [Page 5 & 7]
  • 9MFY25 Revenue (Standalone): Rs. 3,466.79 Crs, up 15.25% YoY [Page 50]

2 more points from Himadri Speciality Chemical Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Himadri Speciality Chemical Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Speciality Carbon Black Expansion: Increase capacity to 130,000 MTPA (world’s largest single-site). Capex Rs. 220 Crores. Brownfield expansion of new 70,000 MTPA line. Scheduled operational by Q3FY26 (Page 29, 19).
  • LFP Cathode Active Material Plant: First commercial plant of 40,000 MTPA. Capex Rs. 1,125 Crores. Scheduled operational by Q3FY27 (Page 19).
  • High Value-Added Speciality Products Facility (Anthraquinone, Carbazole, Fluorene): Capex Rs. 120 Crores from internal accruals. Expected commencement in 18 months (Page 11).

2 more points from Himadri Speciality Chemical Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Himadri Speciality Chemical Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Key points covered include: - Financial performance details (revenue, EBITDA, PAT) for Q3 and 9MFY25. - Sales volumes and growth percentages. - Highlights on Capex for high-value specialty products. - ESG-focused innovations.

2 more points from Himadri Speciality Chemical Ltd's call on order book

Create a free account to keep reading this call

Himadri Speciality Chemical Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Himadri Speciality Chemical Ltd Q3 FY25 results — key figures

Himadri Speciality Chemical Ltd Q3 FY25 reported results vs Q3 FY24, ₹ crore
₹ CrQ3 FY25Q3 FY24YoYQ2 FY25QoQ
Revenue1,1411,053+8.4%1,137+0.4%
Operating profit (EBITDA)221174+27%208+6.3%
Operating margin19%17%+2 pp18%+1 pp
Profit before tax206150+37.3%197+4.6%
Net profit (PAT)141109+29.4%136+3.7%
EPS (₹)2.882.47+16.6%2.74+5.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.7K Cr, net profit ₹231 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Gujarat Alkalies (Q3 FY25)

    3,702.77 Crores (up from Rs. Key concall takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

  • Balaji Amines (Q3 FY25)

    Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Key concall takeaways from Balaji Amines Ltd's Q3…

  • Vidhi Specialty (Q3 FY25)

    Year-on-Year (Y-o-Y) Growth:** 56.5% increase . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY25 earnings call — and how it ranks…

  • Chemcon Speciality Chemicals (Q3 FY25)

    54.4 Cr, up 3% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Himadri Speciality Chemical Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Himadri Speciality Chemical Ltd Q3 FY25 results?

Q3FY25 Revenue (Standalone): Rs. 1,131.81 Crs, up 7.53% YoY (from Rs. 1,052.51 Crs in Q3FY24) [Page 50]. Q3FY25 EBITDA (Standalone): Rs. 222.34 Crs, up 31.79% YoY (Page 49).

What is Himadri Speciality Chemical Ltd share price analysis?

Himadri Speciality Chemical Ltd currently shows a neutral. The stock trades at a P/E of 42.6 with a market cap of ₹34,076 Cr. Investors should review the full earnings analysis for detailed insights.

Is Himadri Speciality Chemical Ltd planning capital expenditure?

Speciality Carbon Black Expansion: Increase capacity to 130,000 MTPA (world’s largest single-site).

Keep Himadri Speciality Chemical Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.